Focusing on New Piperazinyl‐methyl‐3(2 H)pyridazinone Based Derivatives: Design, Synthesis, Anticancer Activity and Computational Studies

Abstract

Heterocyclics containing pyridazinone and piperazine structures are potential anticancer agents in the treatment of cancer disease caused by increasing the number of abnormal cells disrupting body biochemistry. There is a need for the design of more biocompatible drugs for the treatment of cancer with minimal side effects. For this purpose, a series of piperazinyl‐methyl‐3(2 H)pyridazinone based compounds were synthesized and their anticancer activities were studied in vitro and in silico. The chemical structures of all the new compounds 3 (a– k) were identified by spectral analysis. The new compounds were screened in human lung and colon cancer cell lines to learn about their cytotoxic effects. The importance of the structure activity relationship was seen in this study and the compounds containing methoxy groups on the phenyl ring ( 3 a, 3 b, 3 e– 3 g) were found to have higher cytotoxic effects than those without. It was determined that one of these compounds ( 3 a) demonstrated significant cytotoxic effect against both cell lines for 72 h as in vitro. The geometry of the synthesized 3 a ligand was optimized using the hybrid B3LYP functional density functional theory (DFT). Molecular docking study of 3 a compound was performed against EGFR (PDB ID : 1M17) and VEGFR‐2 (PDB ID: 2RL5) molecular targets.